The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities

Ostroukhova E.N.; Khmel'nitskiĭ O.K.; Krasil'nikova E.I.; Davidenko K.S.

doi:https://doi.org/

Ostroukhova E.N.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Khmel'nitskiĭ O.K.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Krasil'nikova E.I.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet

Davidenko K.S.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet

The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities

Authors:

Ostroukhova E.N., Khmel'nitskiĭ O.K., Krasil'nikova E.I., Davidenko K.S.

More about the authors

Journal: Problems of Endocrinology. 2012;58(3): 51‑55

Read: 8444 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ostroukhova EN, Khmel'nitskiĭ OK, Krasil'nikova EI, Davidenko KS. The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities. Problems of Endocrinology. 2012;58(3):51‑55. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Modulation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;(10):108-116

Features of comorbidity pathology in young people. Russian Journal of Preventive Medicine. 2024;(11):63-69

Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68

Options for the surgical technique of laparoscopic sleeve gastrectomy for prevention and treatment of gastroesophageal reflux in patients with obesity. Endoscopic Surgery. 2024;(6):57-68

Application of modern methods for activation of brain functions in obese patients (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):54-61

Comparative analysis of the state of the microvasculature of the oral mucosa in persons with metabolic syndrome in the aspect of orthopedic dental rehabilitation. Stomatology. 2024;(6-2):15-22

Relationship between metabolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63

Chronic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medicine. 2025;(1):115-121

Identification of prognostic significant markers of early diagnosis of obesity and metabolic disorders. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):71-79

Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60

Abstract:

This paper reports the results of the treatment of 71 patients presenting with type 2 diabetes mellitus using liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1) marketed under the brand name Victoza. Practically all the patients experienced either improvement or normalization of the parameters of carbohydrate metabolism in conjunction with a reduction of their body weight and arterial pressure. There were no severe hypoglycemic episodes and other adverse reactions to the therapy. It is recommended that Victoza should be more widely used for the treatment of the patients with type 2 diabetes mellitus.

Keywords:

type 2 diabetes mellitus

obesity

Victoz

Authors:

Ostroukhova E.N.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Khmel'nitskiĭ O.K.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. akad. I.P. Pavlova

Krasil'nikova E.I.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet

Davidenko K.S.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet

Close metadata

References:

IDF diabetes atlas, 5th edition, 2011.
Shestakova M.V. Cakharnyi diabet v pozhilom vozraste: osobennosti kliniki, diagnostiki i lecheniya. Consilium Medicum 2002; Tom 04, № 10. http://old.consilium-medicum.com/media/consilium/02_10/544.shtml
Obesity and Overweight for Professionals: Data and Statistics: U.S. Obesity Trends. Centers for Disease Control and Prevention. 2011-07-21. http://www.cdc.gov/obesity/data/trends.html. Retrieved 2012-10-25
James P.T., Rigby N., Leach R. "The obesity epidemic, metabolic syndrome and future prevention strategies". Eur J Cardiovasc Prev Rehabil 2004; 11 (1): 3-8.
Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom (5-i vypusk). Sakharnyi diabet 2011; №3 (Prilozhenie).
Nauck M.A., Meier J.J. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005; 124 (suppl): 135-148.
Toft-Nielsen M.B., Madsbad S., Holst J.J. Determinants of the effectiveness of glucagonlike peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3853-3860.
Farilla L., Bulotta A., Hirshberg B., Calzi S.L., Khoury N., Noushmehr H., Bertolotto C., Di Mario U., Harlan D.M., Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144(12):5149-5158.
Carnea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 2011; 8:323-338.
Flint A., Raben A., Ersbøll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25 (6): 781-792.
Hayes M.R., Leichner T.M., Zhao S., Lee G.S., Chowansky A., Zimmer D., De Jonghe B.C., Kanoski S.E., Grill H.J., Bence K.K. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 2011; 13(3):320-330.
Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54 (1):146-151.
Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., Beglinger C. Glucagon-like Peptide-1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89(6):3055-3061.
Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43(9):1664-1669.
Elbrønd B., Jakobsen G., Larsen S., Agersø H., Jensen L.B., Rolan P., Sturis J., Hatorp V., Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25 (8):1398-1404.